XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying...
XTL Flat on buying SOCIAL PROXY
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced today it has entered into a definitive share purchase ...